

1 Mendelian randomization analysis revealed causal effects from gut microbiota to
2 abdominal obesity

3

4 Qian Xu,^{a,b} Shan-Shan Zhang,^a Yu-Fang Pei^{a,b,#} Jing-Jing Ni,^{a,c} Lei Zhang,^{b,c}
5 Rui-Rui Wang,^a Yu-Jing Weng,^a Xun Cui,^a Xin-Tong Wei,^{a,b}

6 ^aDepartment of Epidemiology and Health Statistics, School of Public Health,
7 Medical College of Soochow University, Jiangsu, PR China.

8 ^bJiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric
9 Diseases, Medical College of Soochow University, Jiangsu, PR China.

10 ^cCenter for Genetic Epidemiology and Genomics, School of Public Health,
11 Medical College of Soochow University, Jiangsu, PR China.

12

13 Running Head: causal effect from gut microbiota to abdominal obesity

14

15 #Address correspondence to Yu-Fang Pei, ypei@suda.edu.cn

16 Qian Xu and Shan-Shan Zhang contributed equally to this paper. Author order was
17 determined on the basis of authors' contributions.

18 The study provided evidence of causal relationship from family *Barnesiellaceae* to
19 trunk fat mass.

20 The word counts for the abstract are 297 and the word counts for the text are 2408.

21 **ABSTRACT**

22 Although recent studies have revealed the association between the gut microbiota
23 and obesity, the causality remains elusive. We performed a Mendelian
24 Randomization (MR) analysis to determine whether there is a causal relationship
25 between gut microbiota and abdominal obesity. We used a two-sample MR
26 approach to assess the causal effect from gut microbiota to obesity based on
27 genome-wide association studies (GWAS) summary statistics. The GWAS
28 summary statistics of gut microbiota obtained from UK-twins cohort (N=1,126)
29 were used as discovery sample exposure, and the GWAS summary statistics from
30 the Genetic Environmental Microbial (GEM) project (N=1,098) were used as
31 replication sample exposure. Trunk fat mass (TFM) summary statistics from the
32 UK Biobank (UKB) cohort (N=330,762) were used as outcome. Bacteria were
33 grouped into taxa features at family level. A total of 16 families were analyzed in
34 the discovery sample. Family *Barnesiellaceae* was associated with TFM at the
35 nominal significance level ($b=-3.81\times 10^{-4}$, $P=1.96\times 10^{-3}$). The causal association
36 was successfully replicated in the replication sample ($b=-7.34\times 10^{-3}$, $P=2.77\times 10^{-2}$).
37 Our findings provided evidence of causal relationship from microbiota to fat
38 development, and may be helpful in selecting potential causal bacteria for
39 manipulating candidate gut microbiota to therapy obesity.

40 **IMPORTANCE** Obesity, as a global public health problem, is one of the most
41 important risk factors contributing to the overall global burden of disease, and is
42 associated with an increased risk of cardiovascular disease, type 2 diabetes, and

43 certain cancers. Recent studies have shown that gut microbiota is closely related to
44 the development of obesity, but the causal relationship is unclear. Therefore, it is
45 necessary to identify the causality between gut microbiota and obesity. The
46 significance of our research is in identifying the causal relationship from specific
47 bacteria to fat development, which will provide the new insights into the microbiota
48 mediated the fat development mechanism.

49 INTRODUCTION

50 Obesity is a chronic metabolic disease characterized by excessive accumulation of
51 adipose tissue. It is one of the most important risk factors contributing to the
52 overall burden of diseases worldwide, associated with increased risk of
53 cardiovascular disease, type 2 diabetes and certain cancers(1). In 2013, the number
54 of overweight and obese individuals globally has reached 2.1 billion and the
55 prevalence has been increasing substantially(2).

56 Body mass index (BMI), which is defined as body mass in kilograms divided by
57 the square of height in meters (kg/m^2), is currently the standard measure of obesity
58 due to its simplicity. However, BMI is never the ideal phenotype to measure
59 obesity because it does not give a precise idea about the body composition(3).

60 Human body mass is composed of fat mass, lean mass, bone mass, water and soft
61 tissues; it is only fat mass that induces obesity and causes a series of adverse
62 clinical manifestations. Therefore, fat mass is the only accurate and ideal
63 phenotype to measure obesity(4, 5). Nonetheless, the research using fat mass as a
64 measure of obesity has rarely been studied. Among various types of fat-induced
65 obesity, abdominal obesity is perhaps the most severe. Fat stored in the abdomen is
66 more harmful than fat stored at other body regions. For example, fat mass stored
67 more centrally leads people to be more susceptible to cardiovascular diseases and
68 endocrine disorders(6).

69 Even though obesity can be attributable to lifestyle, culture factors and

70 genetics(7-9), mounting evidence demonstrated that the human gut microbiome
71 play an important role in the development of obesity(10-12). Mice models provide
72 the causal evidence of obesity linked to gut microbiome, but the finding are far
73 from consistent(13, 14). A case-control study found the abundance of
74 *Lactobacillus reuteri* was positively correlated with BMI, and *Bifidobacterium*
75 *animalis*, *Methanobrevibacter smithii*, and *Escherichia coli* were negatively
76 associated with BMI(15). A cohort study identified 34 bacterial taxa associated
77 with BMI and explained 4.5% of its variance(16). Nonetheless, the causality
78 between specific taxa of gut microbiota and obesity is still ambiguous due to many
79 confounding factors (including lifestyle, diet and disease status) that occur within
80 the population.

81 Mendelian randomization (MR) analysis is a statistics approach that uses genetic
82 variants as instrumental variables (IVs) to test the causality from potentially risk
83 exposure to health outcomes in a cross-sectional study. It is less likely to be
84 affected by confounding factors or inverse causation than conventional
85 observational studies(17, 18). Previous study has shown that host genetic
86 variations influence the composition of gut microbiota(19). Recent years,
87 increasing genome-wide association studies (GWAS) for gut microbiota(20-24)
88 make it possible to infer causal relationship by performing MR analysis base on
89 summary statistics of GWAS.

90 In the present study, we conduct a two-sample MR study(25) to investigate the

- 91 causal link from specific taxa of gut microbiota to trunk fat mass (TFM) using
- 92 summary statistics of GWAS. Specifically, the summary statistics from microbial
- 93 GWAS serve as exposure while the summary statistics from trunk fat mass GWAS
- 94 serve as outcome.

95 **RESULTES**

96 In the discovery TwinsUK sample, there are total of 229 SNPs associated with gut
97 microbiota at the significance level $P < 1.0 \times 10^{-5}$. After clumping, there were 102
98 SNPs, categorized into 16 bacteria families (**Supplementary table 1**). The family
99 with the largest number SNPs is *Ruminococcaceae* (24 SNPs), followed by
100 *Lachnospiraceae* (23 SNPs) and *Bacteroidaceae* (21 SNPs). There were 6 families
101 each containing only one SNP, *Bifidobacteriaceae*, *Streptococcaceae*,
102 *Veillonellaceae*, *Barnesiellaceae*, *Enterobacteriaceae* and
103 *Porphyromonadaceae*. The number of IV SNPs ranged from 2 to 6 for the remaining
104 7 families.

105 To ensure that the above IVs are free from horizontal pleiotropy, we performed
106 MR-PRESSO analysis on independent SNPs to detect the potential SNPs with
107 pleiotropy effect. One out of 6 IVs in family *Clostridiaceae*, 1 out of 21 IVs in
108 family *Bacteroidaceae*, 3 out of 23 IVs in family *Lachnospiraceae*, 4 out of 24 IVs
109 in family *Ruminococcaceae* and 1 out of 6 IVs in family *Pasteurellaceae* were
110 detected as outliers using the MR-PRESSO outlier test (**Supplementary Table 2**).

111 After removing the SNPs with pleiotropy effect, we performed MR analysis on the
112 remaining SNPs. In the discovery sample, only one family *Barnesiellaceae* is
113 nominally significant level ($\beta = -3.81 \times 10^{-4}$, $P = 1.96 \times 10^{-3}$). Specifically, this family
114 *Barnesiellaceae* contains only one IV SNP rs4897946, which is located in the intron
115 region of *MIER2* gene on chromosome 19 (**Table 1**).

116 The significant family *Barnesiellaceae* is subjected to be replicated in the GEM
117 replication sample. Again, only one SNP rs16901246 is assigned to this family.
118 Interestingly, both the causal effect direction ($\beta = -7.34 \times 10^{-3}$) is consistent with
119 that in the discovery sample and the p-value is significant (0.03), strengthening the
120 confidence towards the true association of this family. The IV SNP rs16901246 is
121 located in the intron region of *CTNND2* gene on chromosome 5.

122 **DISCUSSION**

123 In this study, we performed a two sample MR-based causality analysis between
124 gut microbiota and TFM using summary statistics from GWAS summary statistics.
125 By combining the results from discovery and replication studies, we identified a
126 causal association from bacteria family *Barnesiellaceae* to TFM. Specifically, our
127 results demonstrated a reverse causal effect from the former to the latter.

128 The gut microbiota of healthy adult was primarily dominated by two phyla
129 *Firmicutes* (53.9% of total) and *Bacteroidetes* (35.3%), with other phyla including
130 *proteobacteria*, *Verrucomicrobia*, *Actinobacteria*, and *Tenericutes*(26, 27). Previous
131 studies have shown the relative abundance of *Firmicutes* and *Bacteroidetes* in obese
132 populations. For example, a twins study revealed that the proportion of
133 *Bacteroidetes* is higher in obese compared with lean individuals(12). Another animal
134 study found a reduction in the abundance of *Bacteroidetes* together with a relative
135 increase in *Firmicutes* in obese animals compared with lean animals(13). The family
136 *Barnesiellaceae* identified in the present study is a member of *Bacteroidetes* phylum.
137 A recent study found that the family *Barnesiellaceae* was correlated with the
138 percentage of body fat and modified by exercise(28). In a case-control study,
139 Chierico et al reported the abundance of family *Barnesiellaceae* may be a microbial
140 biomarker in healthy adolescents(29). These previous observational studies provide
141 valuable clues towards the close relationship between *Barnesiellaceae* and fat mass
142 development. For the first time, to our best knowledge, the present study established

143 a causal link from the former to the latter.

144 A possible mechanism of gut microbiota influence the development of obesity is that
145 gut microbiota can increase energy production from diet, contribute to low-grade
146 inflammation and regulate fatty acid tissue composition(30). Though it remains
147 unclear for the mechanism underlying the regulator path from *Barnesiellaceae* to
148 obesity development, previous study showed that the *Barnesiellaceae* has been
149 associated with low-fiber consuming(31). Another study found the relative
150 abundance of *Barnesiellaceae* clearly decreased in a medium containing only
151 proteins and peptones, which revealed it not involve in protein breakdown and
152 fermentation(32). However, further functional investigation is warranted to validate
153 this correlation.

154 The MR approach is robust to confounding factors and reverse causality in
155 observational studies (33). In this study, we applied a two sample MR approach
156 based on summary statistics to explore the causal relationship between gut
157 microbiota and TFM. Our study has following advantages. First, it is based on
158 large-scale GWAS summary statistics that are publicly available, thus offers an
159 efficient option to mine reliable genetic information without additional experiment
160 costs. Second, we used TFM instead of BMI as a phenotype to measure abdominal
161 obesity, which provided exactly accurate risk information of obesity.

162 However, there are also some limitations in our study. Firstly, the gut microbiota
163 GWAS is still scarce, resulting in very limited t gut microbiota-associated SNPs to

164 be used for analysis. Secondly, the significant causal association identified in this
165 study were obtained using single IV, which has inferior robustness and statistical
166 power.

167 In conclusion, by performing a two sample MR analysis based on several GWAS
168 summary statistics, we identified a causal relationship from gut microbiota to
169 abdominal obesity. Our results may be helpful in selecting potential causal bacteria
170 for manipulating candidate gut microbiota to therapy obesity.

171 **MATERIALS AND METHODS**

172 *Ethics statement*

173 Gut microbiota GWAS summary statistics were accessed from published studies.

174 No new IRB approval was required.

175 Trunk fat mass sample came from the UKB cohort, which is a large prospective
176 cohort study of ~500,000 participants from across the United Kingdom, aged
177 between 40-69 at recruitment. Ethics approval for the UKB study was obtained
178 from the North West Centre for Research Ethics Committee (11/NW/0382), and
179 informed consent was obtained from all participants. This study (project number
180 41542) was covered by the general ethical approval for the UKB study.

181 *GWAS summary statistics for gut microbiota*

182 For exposure, we collected publicly available GWAS summary statistics of gut
183 microbiota from two independent studies: the TwinsUK study and the Canada
184 Genetic Environmental Microbial (GEM) project study. The TwinsUK study was
185 used as discovery sample and it consisted of 489 dizygotic (DZ) twin pairs and
186 637 monozygotic (MZ) twin pairs with an age range of 18-89 years(22). The GEM
187 project was used as replication sample, which included 1,098 healthy first-degree
188 relatives of patients with Crohns disease between 6 and 35 years of age (24). Stool
189 collection, DNA extraction, 16 sRNA gene sequencing and taxa filtering were
190 performed on both cohorts.

191 In the discovery sample, the genetic associations between 945 bacteria taxa and
192 1,300,091 host SNPs were tested. A total of 307 host SNPs were identified to be
193 associated with 61 bacteria taxa (1 kingdom + 6 phyla + 9 classes + 9 orders + 16
194 families + 16 genera + 4 species) at a $FDR < 0.2$. The P values at these SNPs
195 ranged from 4.94×10^{-9} to 7.33×10^{-5} . The summary statistics of these significant
196 SNPs were assessed through the supplemental table of the study publication(22).

197 In the replication sample, the associations between 3,727,707 host SNPs and 166
198 non-redundant bacterial taxa were examined. A total of 58 SNPs were identified to
199 be associated with the relative abundance of 33 taxa at the genome-wide
200 significance level ($P < 5 \times 10^{-8}$). The summary statistics of these significant SNPs
201 were assessed through the supplemental table of the study publication(24).

202 *UKB trunk fat mass sample*

203 All the included participants in the UKB sample are those who self-reported as
204 white (data field 21000). Participants who had a self-reported gender inconsistent
205 with the genetic gender, who were genotyped but not imputed or who withdrew
206 their consents were removed.

207 Trunk fat mass (TFM) was measured by bioelectrical impedance analysis approach.
208 Phenotypic outliers were monitored by the Tukey method. Covariates, including
209 age, sex, assessment center (23 levels), genotyping batch (2 levels) and the top 10
210 principal components (PCs) derived from genome-wide genotype data, were used
211 to adjust raw phenotype. The residuals were normalized into inverse quantiles of

212 standard normal distribution, which were used for subsequent association analysis.

213 Genome-wide genotypes were available for all participants at 784,256 genotyped

214 autosome markers, and were imputed into UK10K haplotype, 1000 Genomes

215 project phase 3 and Haplotype Reference Consortium (HRC) reference panels. A

216 total of ~92 million variants were generated by imputation.

217 We used BOLT-LMM to perform linear mixed model (LMM) analysis of genetic

218 association. The LMM analysis can adjust for population structure and relatedness.

219 *Genetic instrumental variants selection*

220 Based on the GWAS summary results of gut microbiota, a series of quality control

221 (QC) criteria were applied to select eligible genetic instrumental variables (IVs).

222 Specifically, bacteria taxa were analyzed at the family level. A feature was defined

223 as a distinct family. For SNP with multiple signals within one feature, the strongest

224 signal was selected for that feature.

225 In the discovery sample, SNPs associated with microbiota at the $\alpha=1\times 10^{-5}$ level

226 were selected and assigned into distinct features. The SNPs within each feature

227 were then clumped with PLINK (v1.9) to retain independent SNPs only. For

228 clumping The linkage disequilibrium (LD) threshold was set to be $r^2<0.1$ and the

229 clumping window size was set to be 500 kb, where LD was estimated based on the

230 1000 genomes project sequencing data (phase 3).

231 In the replication sample, SNPs of association at the same $\alpha=1\times 10^{-5}$ were not

232 accessible. In contrast, only SNPs significant at the $\alpha=5\times 10^{-8}$ level were reported.
233 Therefore, all the reported SNPs were selected. SNPs were again assigned into
234 features and clumped to retain independent SNPs, following the same steps as
235 those used in the discovery sample.

236 ***Removal of horizontal pleiotropy***

237 We applied the MR-PRESSO Global test(34) and Outlier test to detect potential
238 horizontal pleiotropy. The MR-PRESSO global test evaluates overall horizontal
239 pleiotropy among all SNPs, and the MR-PRESSO Outlier test evaluates the
240 presence of specific horizontal pleiotropic outlier variants by calculating the
241 p-value of each SNP pleiotropy significance. The MR-PRESSO global test was
242 first applied to evaluate overall pleiotropy. In the presence of pleiotropy, the
243 MR-PRESSO Outlier test was then applied and the SNP with the smallest
244 pleiotropy p-value was removed. The MR-PRESSO Global test was again
245 performed on the remaining SNPs. The process repeated until the Global test was
246 non-significant ($P>0.05$).

247 The final retained SNPs were used as non-pleiotropic IVs to perform subsequent
248 Mendelian randomization analysis.

249 ***Mendelian randomization analysis***

250 We performed two sample MR analysis to examine the causal effect from bacteria
251 taxa to TFM. Specifically, we tested the association of the identified IVs within
252 each bacteria taxa with TFM. For bacteria taxa containing multiple SNPs, we used

253 five methods to estimate the causal effect, including the inverse variance weighted
254 (IVW) test(35), the MR-Egger regression(36), the weighted median estimator(37),
255 the simple mode-based estimator and the weighted mode-based estimator(38). The
256 results were mainly based on the IVW method while the other 4 methods served as its
257 complement. For bacteria taxa containing only one SNP, the Wald Ratio method
258 was used for MR analysis. This method calculates the causal effect by using the
259 coefficient of the SNP-outcome association divided by the coefficient of the
260 SNP-exposure association(39).

261 Significant families identified in the discovery TwinsUK study were subjected to
262 be replicated in the replication GEM study, following the same MR analysis
263 procedure.

264 All the above analyses were performed with the R packages *TwoSampleMR*
265 (<https://github.com/MRCIEU/TwoSampleMR>)(40) and *MR-PRESSO*
266 (<https://github.com/rondolab/MR-PRESSO>)(34)

267 **ACKNOWLEDGMENT**

268 This research was conducted using the UK Biobank resource under application
269 number 41542. We appreciate all the volunteers who participated in this study. We
270 are grateful to the TwinsUK study and the Genetic Environmental Microbial
271 (GEM) project for releasing the gut microbiota GWAS summary statistics.

272 YFP and LZ are partially supported by the funding from national natural science
273 foundation of China (31771417 and 31571291) a project funded by the Priority
274 Academic Program Development (PAPD) of Jiangsu higher education institutions
275 and the Undergraduate Training Program for Innovation and Entrepreneurship,
276 Soochow University (201810285048Z). The numerical calculations in this paper
277 have been done on the supercomputing system of the National Supercomputing
278 Center in Changsha.

279 REFERENCES

- 280 1. Haslam DW, James WP (ed). 2005. Obesity.
- 281 2. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, Mullany EC, Biryukov S,
282 Abbafati C, Abera SF, Abraham JP, Abu-Rmeileh NM, Achoki T, AlBuhairan FS, Alemu ZA,
283 Alfonso R, Ali MK, Ali R, Guzman NA, Ammar W, Anwari P, Banerjee A, Barquera S, Basu S,
284 Bennett DA, Bhutta Z, Blore J, Cabral N, Nonato IC, Chang JC, Chowdhury R, Courville KJ,
285 Criqui MH, Cundiff DK, Dabhadkar KC, Dandona L, Davis A, Dayama A, Dharmaratne SD,
286 Ding EL, Durrani AM, Esteghamati A, Farzadfar F, Fay DF, Feigin VL, Flaxman A,
287 Forouzanfar MH, Goto A, Green MA, Gupta R, et al. 2014. Global, regional, and national
288 prevalence of overweight and obesity in children and adults during 1980-2013: a
289 systematic analysis for the Global Burden of Disease Study 2013. *Lancet* 384:766-81.
- 290 3. Engin A. 2017. The Definition and Prevalence of Obesity and Metabolic Syndrome. *Adv*
291 *Exp Med Biol* 960:1-17.
- 292 4. Frankenfield DC, Rowe WA, Cooney RN, Smith JS, Becker D. 2001. Limits of body mass
293 index to detect obesity and predict body composition. *Nutrition* 17:26-30.
- 294 5. Liu P, Ma F, Lou H, Liu Y. 2013. The utility of fat mass index vs. body mass index and
295 percentage of body fat in the screening of metabolic syndrome. *BMC Public Health*
296 13:629.
- 297 6. Pischon T, Boeing H, Hoffmann K, Bergmann M, Med ERJNEJ. 2008. General and
298 Abdominal Adiposity and Risk of Death in Europe. 359:2105-2120.
- 299 7. Pei YF, Ren HG, Liu L, Li X, Fang C, Huang Y, Hu WZ, Kong WW, Feng AP, You XY, Zhao W,
300 Shen H, Tian Q, Zhang YH, Deng HW, Zhang L. 2017. Genomic variants at 20p11
301 associated with body fat mass in the European population. *Obesity (Silver Spring)*
302 25:757-764.
- 303 8. Liu L, Pei YF, Liu TL, Hu WZ, Yang XL, Li SC, Hai R, Ran S, Zhao LJ, Shen H, Tian Q, Xiao HM,
304 Zhang K, Deng HW, Zhang L. 2019. Identification of a 1p21 independent functional
305 variant for abdominal obesity. *Int J Obes (Lond)* 43:2480-2490.
- 306 9. Chatham RE, Mixer SJ. 2020. Cultural Influences on Childhood Obesity in Ethnic
307 Minorities: A Qualitative Systematic Review. *J Transcult Nurs* 31:87-99.
- 308 10. Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. 2014. Gut
309 microbiota and metabolic syndrome. *World J Gastroenterol* 20:16079-94.
- 310 11. Okeke F, Roland BC, Mullin GE. 2014. The role of the gut microbiome in the pathogenesis

- 311 and treatment of obesity. *Glob Adv Health Med* 3:44-57.
- 312 12. Turnbaugh PJ, Hamady M, Yatsunencko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones
313 WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI. 2009. A
314 core gut microbiome in obese and lean twins. *Nature* 457:480-4.
- 315 13. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. 2005. Obesity alters
316 gut microbial ecology. *Proc Natl Acad Sci U S A* 102:11070-5.
- 317 14. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. 2006. An
318 obesity-associated gut microbiome with increased capacity for energy harvest. *Nature*
319 444:1027-31.
- 320 15. Million M, Angelakis E, Maraninchi M, Henry M, Giorgi R, Valero R, Vialettes B, Raoult D.
321 2013. Correlation between body mass index and gut concentrations of *Lactobacillus*
322 *reuteri*, *Bifidobacterium animalis*, *Methanobrevibacter smithii* and *Escherichia coli*. *Int J*
323 *Obes (Lond)* 37:1460-6.
- 324 16. Fu J, Bonder MJ, Cenit MC, Tigchelaar EF, Maatman A, Dekens JA, Brandsma E,
325 Marczyńska J, Imhann F, Weersma RK, Franke L, Poon TW, Xavier RJ, Gevers D, Hofker MH,
326 Wijmenga C, Zhernakova A. 2015. The Gut Microbiome Contributes to a Substantial
327 Proportion of the Variation in Blood Lipids. *Circ Res* 117:817-24.
- 328 17. Evans DM, Davey Smith G. 2015. Mendelian Randomization: New Applications in the
329 Coming Age of Hypothesis-Free Causality. *Annu Rev Genomics Hum Genet* 16:327-50.
- 330 18. Davies NM, Holmes MV, Davey Smith G. 2018. Reading Mendelian randomisation studies:
331 a guide, glossary, and checklist for clinicians. *Bmj* 362:k601.
- 332 19. Org E, Parks BW, Joo JW, Emert B, Schwartzman W, Kang EY, Mehrabian M, Pan C, Knight
333 R, Gunsalus R, Drake TA, Eskin E, Lusk AJ. 2015. Genetic and environmental control of
334 host-gut microbiota interactions. *Genome Res* 25:1558-69.
- 335 20. Davenport ER, Cusanovich DA, Michelini K, Barreiro LB, Ober C, Gilad Y. 2015.
336 Genome-Wide Association Studies of the Human Gut Microbiota. *PLoS One*
337 10:e0140301.
- 338 21. Bonder MJ, Kurilshikov A, Tigchelaar EF, Mujagic Z, Imhann F, Vila AV, Deelen P, Vatanen T,
339 Schirmer M, Smeekens SP, Zhernakova DV, Jankipersadsing SA, Jaeger M, Oosting M,
340 Cenit MC, Masclee AA, Swertz MA, Li Y, Kumar V, Joosten L, Harmsen H, Weersma RK,
341 Franke L, Hofker MH, Xavier RJ, Jonkers D, Netea MG, Wijmenga C, Fu J, Zhernakova A.
342 2016. The effect of host genetics on the gut microbiome. *Nat Genet* 48:1407-1412.

- 343 22. Goodrich JK, Davenport ER, Beaumont M, Jackson MA, Knight R, Ober C, Spector TD, Bell
344 JT, Clark AG, Ley RE. 2016. Genetic Determinants of the Gut Microbiome in UK Twins. *Cell*
345 *Host Microbe* 19:731-43.
- 346 23. Wang J, Thingholm LB, Skieceviciene J, Rausch P, Kummen M, Hov JR, Degenhardt F,
347 Heinsen FA, Ruhlemann MC, Szymczak S, Holm K, Esko T, Sun J, Pricop-Jeckstadt M,
348 Al-Dury S, Bohov P, Bethune J, Sommer F, Ellinghaus D, Berge RK, Hubenthal M, Koch M,
349 Schwarz K, Rimbach G, Hubbe P, Pan WH, Sheibani-Tezerji R, Hasler R, Rosenstiel P,
350 D'Amato M, Cloppenborg-Schmidt K, Kunzel S, Laudes M, Marschall HU, Lieb W,
351 Nothlings U, Karlsten TH, Baines JF, Franke A. 2016. Genome-wide association analysis
352 identifies variation in vitamin D receptor and other host factors influencing the gut
353 microbiota. *Nat Genet* 48:1396-1406.
- 354 24. Turpin W, Espin-Garcia O, Xu W, Silverberg MS, Kevans D, Smith MI, Guttman DS, Griffiths
355 A, Panaccione R, Otley A, Xu L, Shestopaloff K, Moreno-Hagelsieb G, Paterson AD,
356 Croitoru K. 2016. Association of host genome with intestinal microbial composition in a
357 large healthy cohort. *Nat Genet* 48:1413-1417.
- 358 25. Lawlor DA. 2016. Commentary: Two-sample Mendelian randomization: opportunities
359 and challenges. *Int J Epidemiol* 45:908-15.
- 360 26. Dethlefsen L, McFall-Ngai M, Relman DA. 2007. An ecological and evolutionary
361 perspective on human-microbe mutualism and disease. *Nature* 449:811-8.
- 362 27. Anonymous. 2012. Structure, function and diversity of the healthy human microbiome.
363 *Nature* 486:207-14.
- 364 28. Bressa C, Bailen-Andrino M, Perez-Santiago J, Gonzalez-Soltero R, Perez M,
365 Montalvo-Lominchar MG, Mate-Munoz JL, Dominguez R, Moreno D, Larrosa M. 2017.
366 Differences in gut microbiota profile between women with active lifestyle and sedentary
367 women. *PLoS One* 12:e0171352.
- 368 29. Del Chierico F, Abbatini F, Russo A, Quagliariello A, Reddel S, Capoccia D, Caccamo R,
369 Ginanni Corradini S, Nobili V, De Peppo F, Dallapiccola B, Leonetti F, Silecchia G, Putignani
370 L. 2018. Gut Microbiota Markers in Obese Adolescent and Adult Patients:
371 Age-Dependent Differential Patterns. *Front Microbiol* 9:1210.
- 372 30. Cox AJ, West NP, Cripps AWJLDE. Obesity, inflammation, and the gut microbiota.
373 *3:207-215*.
- 374 31. Whisner CM, Maldonado J, Dente B, Krajmalnik-Brown R, Bruening M. 2018. Diet,
375 physical activity and screen time but not body mass index are associated with the gut
376 microbiome of a diverse cohort of college students living in university housing: a

- 377 cross-sectional study. *BMC Microbiol* 18:210.
- 378 32. Amaretti A, Gozzoli C, Simone M, Raimondi S, Righini L, Perez-Brocal V, Garcia-Lopez R,
379 Moya A, Rossi M. 2019. Profiling of Protein Degraders in Cultures of Human Gut
380 Microbiota. *Front Microbiol* 10:2614.
- 381 33. Grover S, Del Greco M. F, Stein CM, Ziegler A. 2017. Mendelian Randomization, p
382 581-628. *In* Elston RC (ed), *Statistical Human Genetics: Methods and Protocols*
383 doi:10.1007/978-1-4939-7274-6_29. Springer New York, New York, NY.
- 384 34. Verbanck M, Chen CY, Neale B, Do R. 2018. Detection of widespread horizontal
385 pleiotropy in causal relationships inferred from Mendelian randomization between
386 complex traits and diseases. *Nat Genet* 50:693-698.
- 387 35. Burgess S, Butterworth A, Thompson SG. 2013. Mendelian randomization analysis with
388 multiple genetic variants using summarized data. *Genet Epidemiol* 37:658-65.
- 389 36. Bowden J, Davey Smith G, Burgess S. 2015. Mendelian randomization with invalid
390 instruments: effect estimation and bias detection through Egger regression. *Int J*
391 *Epidemiol* 44:512-25.
- 392 37. Bowden J, Davey Smith G, Haycock PC, Burgess S. 2016. Consistent Estimation in
393 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
394 Estimator. *Genet Epidemiol* 40:304-14.
- 395 38. Hartwig FP, Davey Smith G, Bowden J. 2017. Robust inference in summary data
396 Mendelian randomization via the zero modal pleiotropy assumption. *Int J Epidemiol*
397 46:1985-1998.
- 398 39. Hwang LD, Lawlor DA, Freathy RM, Evans DM, Warrington NM. 2019. Using a two-sample
399 Mendelian randomization design to investigate a possible causal effect of maternal lipid
400 concentrations on offspring birth weight. *Int J Epidemiol* 48:1457-1467.
- 401 40. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S,
402 Bowden J, Langdon R, Tan VY, Yarmolinsky J, Shihab HA, Timpson NJ, Evans DM, Relton C,
403 Martin RM, Davey Smith G, Gaunt TR, Haycock PC. 2018. The MR-Base platform supports
404 systematic causal inference across the human phenome. *Elife* 7.

405

406

Table 1 Causal estimations of gut microbiome on trunk fat mass in the discovery and replication cohorts

stage	Gut microbiota	MR test		SNP	Nearby gene
		b_{xy}	P-value		
Discovery	Family <i>Barnesiellaceae</i>	-3.81×10^{-4}	1.96×10^{-3}	rs4897946	<i>MIER2</i>
Replication		-7.34×10^{-3}	2.77×10^{-2}	rs16901246	<i>CTNND2</i>

407

Notes: b_{xy} is the estimated effect coefficient. Significant p-values were marked in bold.